These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 21177912)

  • 1. Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine and a quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135, and Y in adults who are at increased risk for occupational exposure to meningococcal isolates.
    Kimura A; Toneatto D; Kleinschmidt A; Wang H; Dull P
    Clin Vaccine Immunol; 2011 Mar; 18(3):483-6. PubMed ID: 21177912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents.
    Saez-Llorens X; Aguilera Vaca DC; Abarca K; Maho E; Graña MG; Heijnen E; Smolenov I; Dull PM
    Hum Vaccin Immunother; 2015; 11(6):1507-17. PubMed ID: 25969894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
    Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
    Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and Safety of Investigational MenABCWY Vaccine and of 4CMenB and MenACWY Vaccines Administered Concomitantly or Alone: a Phase 2 Randomized Study of Adolescents and Young Adults.
    Beran J; Dražan D; Enweonye I; Bhusal C; Toneatto D
    mSphere; 2021 Dec; 6(6):e0055321. PubMed ID: 34787449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and safety of the 4CMenB and MenACWY-CRM meningococcal vaccines administered concomitantly in infants: A phase 3b, randomized controlled trial.
    Macias Parra M; Gentile A; Vazquez Narvaez JA; Capdevila A; Minguez A; Carrascal M; Willemsen A; Bhusal C; Toneatto D
    Vaccine; 2018 Nov; 36(50):7609-7617. PubMed ID: 30414782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents.
    Jackson LA; Baxter R; Reisinger K; Karsten A; Shah J; Bedell L; Dull PM;
    Clin Infect Dis; 2009 Jul; 49(1):e1-10. PubMed ID: 19476428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra.
    Reisinger KS; Baxter R; Block SL; Shah J; Bedell L; Dull PM
    Clin Vaccine Immunol; 2009 Dec; 16(12):1810-5. PubMed ID: 19812260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine.
    Read RC; Dull P; Bai X; Nolan K; Findlow J; Bazaz R; Kleinschmidt A; McCarthy M; Wang H; Toneatto D; Borrow R
    Vaccine; 2017 Jan; 35(3):427-434. PubMed ID: 27912986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a novel quadrivalent meningococcal conjugate vaccine (MenACWY-CRM) in healthy Korean adolescents and adults.
    Lee HJ; Chung MH; Kim WJ; Hong YJ; Choi KM; Lee J; Oh CE; Welsch JA; Kim KH; Hong KB; Dagnew AF; Bock H; Dull PM; Odrljin T
    Int J Infect Dis; 2014 Nov; 28():204-10. PubMed ID: 25316331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Izu A; Odrljin T; Dull P
    J Pediatr; 2014 Jun; 164(6):1409-15.e4. PubMed ID: 24657122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
    Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine in Healthy Meningococcal-Naïve Children 2-9 Years of Age: A Phase III, Randomized Study.
    Baccarini CI; Simon MW; Brandon D; Christensen S; Jordanov E; Dhingra MS
    Pediatr Infect Dis J; 2020 Oct; 39(10):955-960. PubMed ID: 32852352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study.
    Klein NP; Habanec T; Kosina P; Shah NR; Kolhe D; Miller JM; Hezareh M; Van der Wielen M
    Vaccine; 2018 Apr; 36(17):2356-2363. PubMed ID: 29576307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine.
    Robertson CA; Greenberg DP; Hedrick J; Pichichero M; Decker MD; Saunders M
    Vaccine; 2016 Oct; 34(44):5273-5278. PubMed ID: 27642132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
    Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents.
    Jackson LA; Jacobson RM; Reisinger KS; Anemona A; Danzig LE; Dull PM
    Pediatr Infect Dis J; 2009 Feb; 28(2):86-91. PubMed ID: 19116603
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers.
    Halperin SA; Diaz-Mitoma F; Dull P; Anemona A; Ceddia F
    Eur J Clin Microbiol Infect Dis; 2010 Mar; 29(3):259-67. PubMed ID: 20033465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.